Search research articles
Contact Us
Filters
Showing results (211-220 of 227) with videos related to
Page
of 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 2021
Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Xiaohua Wu, Jianqing Zhu, Jing Wang, et al.
Communications Medicine
|
April 21, 2026
Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study
Xiaohua Wu, Danbo Wang, Jing Wang, et al.
Chinese Medical Journal
|
June 9, 2026
Tisotumab vedotin versus chemotherapy in Chinese patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy
Lingying Wu, Lihong Chen, Dapeng Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2021
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer
Ning Li, Hualei Bu, Jihong Liu, et al.
Nature Medicine
|
May 15, 2024
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
Xiaohua Wu, Jihong Liu, Jing Wang, et al.
Experimental Hematology & Oncology
|
November 22, 2025
Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors
Rongrui Liu, Rongbo Lin, Ning Li, et al.
The Lancet. Oncology
|
September 14, 2024
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial
Zikun Peng, Huayi Li, Yunong Gao, et al.
JAMA Oncology
|
July 13, 2023
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial
Ning Li, Jianqing Zhu, Rutie Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
Lingfang Xia, Keqiang Zhang, Ying Tang, et al.
Nature Communications
|
December 21, 2025
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial
Xiaohua Wu, Jing Wang, Danbo Wang, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 227) with videos related to
Sort By:
Page
of 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 2021
Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Xiaohua Wu, Jianqing Zhu, Jing Wang, et al.
Communications Medicine
|
April 21, 2026
Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study
Xiaohua Wu, Danbo Wang, Jing Wang, et al.
Chinese Medical Journal
|
June 9, 2026
Tisotumab vedotin versus chemotherapy in Chinese patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy
Lingying Wu, Lihong Chen, Dapeng Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2021
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer
Ning Li, Hualei Bu, Jihong Liu, et al.
Nature Medicine
|
May 15, 2024
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
Xiaohua Wu, Jihong Liu, Jing Wang, et al.
Experimental Hematology & Oncology
|
November 22, 2025
Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors
Rongrui Liu, Rongbo Lin, Ning Li, et al.
The Lancet. Oncology
|
September 14, 2024
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial
Zikun Peng, Huayi Li, Yunong Gao, et al.
JAMA Oncology
|
July 13, 2023
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial
Ning Li, Jianqing Zhu, Rutie Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
Lingfang Xia, Keqiang Zhang, Ying Tang, et al.
Nature Communications
|
December 21, 2025
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial
Xiaohua Wu, Jing Wang, Danbo Wang, et al.
Page
of 23